Lung cancer : treatment and research /: treatment and research. (2016)
- Record Type:
- Book
- Title:
- Lung cancer : treatment and research /: treatment and research. (2016)
- Main Title:
- Lung cancer : treatment and research
- Further Information:
- Note: Karen L. Reckamp, editor.
- Editors:
- Reckamp, Karen L
- Contents:
- 1 Lung Cancer Screening; Abstract; 1 Why Screen for Lung Cancer?; 2 Screening with Chest X-Ray and Sputum Cytologic Studies; 3 Screening with Low-Dose CT of the Chest; 4 Benefits and Risks of LDCT Screening; 5 Guidelines for LDCT Screening; 6 Conclusions; References; 2 Diagnosis and Molecular Classification of Lung Cancer; Abstract; 1 Introduction; 2 Histological Classification of NSCLC; 2.1 Adenocarcinoma (ADC); 2.2 Squamous Cell Carcinoma (SqCC); 2.3 Large-Cell Lung Carcinoma (LCLC); 3 Molecular Alterations of NSCLC; 3.1 Epidermal Growth Factor Receptor (EGFR) 3.2 Anaplastic Lymphoma Kinase (ALK)3.3 Human Epidermal Growth Factor Receptor 2 (HER2); 3.4 ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS); 3.5 Ret Proto-Oncogene (RET); 3.6 NTRK1 (TrkA) Fusions; 3.7 MET; 3.8 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS); 3.9 B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF); 3.10 Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS); 3.11 v-AKT Murine Thymoma Viral Oncogene Homolog 1 (AKT1); 3.12 Mitogen-Activated Protein Kinase 1 (MAP2K1); 3.13 Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha (PIK3CA) 4 Diagnostic and Molecular Testing of NSCLC4.1 Pathological Diagnosis of NSCLC; 4.1.1 Thyroid Transcription Factor 1 (TTF-1); 4.1.2 p40; 4.1.3 Mucicarmin; 4.2 Molecular Testing of NSCLC; 5 Future Directions: Immunotherapy Revolution and Its Integration with Lung Cancer Diagnostics and Therapy; 6 Conclusions; References; 3 Lung Cancer Staging and1 Lung Cancer Screening; Abstract; 1 Why Screen for Lung Cancer?; 2 Screening with Chest X-Ray and Sputum Cytologic Studies; 3 Screening with Low-Dose CT of the Chest; 4 Benefits and Risks of LDCT Screening; 5 Guidelines for LDCT Screening; 6 Conclusions; References; 2 Diagnosis and Molecular Classification of Lung Cancer; Abstract; 1 Introduction; 2 Histological Classification of NSCLC; 2.1 Adenocarcinoma (ADC); 2.2 Squamous Cell Carcinoma (SqCC); 2.3 Large-Cell Lung Carcinoma (LCLC); 3 Molecular Alterations of NSCLC; 3.1 Epidermal Growth Factor Receptor (EGFR) 3.2 Anaplastic Lymphoma Kinase (ALK)3.3 Human Epidermal Growth Factor Receptor 2 (HER2); 3.4 ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS); 3.5 Ret Proto-Oncogene (RET); 3.6 NTRK1 (TrkA) Fusions; 3.7 MET; 3.8 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS); 3.9 B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF); 3.10 Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS); 3.11 v-AKT Murine Thymoma Viral Oncogene Homolog 1 (AKT1); 3.12 Mitogen-Activated Protein Kinase 1 (MAP2K1); 3.13 Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha (PIK3CA) 4 Diagnostic and Molecular Testing of NSCLC4.1 Pathological Diagnosis of NSCLC; 4.1.1 Thyroid Transcription Factor 1 (TTF-1); 4.1.2 p40; 4.1.3 Mucicarmin; 4.2 Molecular Testing of NSCLC; 5 Future Directions: Immunotherapy Revolution and Its Integration with Lung Cancer Diagnostics and Therapy; 6 Conclusions; References; 3 Lung Cancer Staging and Prognosis; Abstract; 1 Lung Cancer Overview; 2 Lung Cancer Staging; 2.1 History of Lung Cancer Staging; 2.2 Non-small Cell Lung Cancer Staging; 2.2.1 IALSC NSCLC TNM Descriptors; 2.2.2 Synchronous Tumor Nodules; 2.3 Pulmonary Carcinoid Tumor Staging 2.4 Small Cell Lung Cancer Staging3 Prognosis; 3.1 Stage-Based Survival Outcomes; 3.2 Clinical and Demographic Prognostication; 3.3 Biomarkers and Genetic Prognostic Indicators; 3.4 Predictive Biomarkers; 3.5 Immunotherapy and Prognosis; 3.6 The Future of NSCLC Prognostication; References; 4 Surgical Treatment of Lung Cancer; Abstract; 1 Introduction; 2 Preoperative Evaluation; 2.1 Radiographic Staging; 2.2 Tissue Diagnosis; 2.3 Physiologic Pulmonary Evaluation; 2.4 Cardiac Evaluation; 2.5 Mediastinal Staging; 3 Surgery and Small-Cell Lung Cancer (SCLC); 4 Non-Small-Cell Lung Cancer (NSCLC) 4.1 Stage IA4.2 Stage IB; 4.3 Stage IIB; 4.4 Stage III NSCLC; 4.4.1 Stage IIIA (e.g., T3N1/T4N1); 4.4.2 Stage IIIA with N2 Disease; 4.5 Stage IIIB and IV NSCLC; 4.6 Special Situations; 4.6.1 Extended Resections; 4.6.2 Synchronous NSCLC; 4.6.3 Oligometastatic Disease; 5 Surgical Options and Approaches; 5.1 Types of Incisions; 5.2 Types of Surgical Resection; 5.2.1 Wedge Resection; 5.2.2 Segmentectomy; 5.2.3 Lobectomy; 5.2.4 Pneumonectomy; 5.2.5 Sleeve Resections; 5.2.6 Carinal Resection; 6 Summary; Bibliography; 5 Treatment: Radiation Therapy; Abstract; 1 Stage I-II Disease … (more)
- Publisher Details:
- Switzerland : Springer
- Publication Date:
- 2016
- Extent:
- 1 online resource (vi, 322 pages), illustrations (some color)
- Subjects:
- 616.99/42406
610
Medicine
Lungs -- Cancer -- Treatment
Oncology
Thoracic surgery
Radiotherapy
Lungs -- Cancer -- Treatment
HEALTH & FITNESS / Diseases / General
MEDICAL / Clinical Medicine
MEDICAL / Diseases
MEDICAL / Evidence-Based Medicine
MEDICAL / Internal Medicine
Medical -- Surgery -- Thoracic
Medical -- Radiology & Nuclear Medicine
Cardiothoracic surgery
Radiotherapy
Medical -- Oncology
Oncology
Lung Neoplasms -- therapy
Electronic books - Languages:
- English
- ISBNs:
- 9783319403892
3319403893 - Related ISBNs:
- 9783319403878
3319403877 - Notes:
- Note: Online resource; title from PDF title page (SpringerLink, viewed August 29, 2016).
- Access Rights:
- Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
- Access Usage:
- Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD.DS.356191
- Ingest File:
- 02_338.xml